Cyclica, a biotechnology company announced its novel, first-in-class drug design technology, Ligand DesignTM at the Collision Conference in Toronto.
Ligand DesignTM provides scientists with an opportunity to generate novel drug-like compounds by combining powerful methods for molecule generation, ADMET prediction, and high-throughput Ligand-protein interaction prediction.
Ligand design is a classical computational drug design approach, like virtual screening, focus on a single protein target. The phenomenon of one drug acting on multiple proteins in the body, or a drug’s pharmacokinetic properties, describes how a drug is absorbed and processed by the body.
Ligand Design's single target focuses on a drug’s polypharmacology and explores synthetically accessible chemical space to de novo design small molecules against a collection of targets and anti-targets, while simultaneously selecting for physicochemical and ADMET properties.
Ligand DesignTM has the ability to transform research and discovery processes and augment the capabilities of scientists to rapidly design drugs with greater precision and efficacy.
The novel platform is showing promising results in the drug discovery. To date, several novel agents have been synthesized and tested successfully for activity in multiple disease areas.
